Skip to content

The clinical effectiveness of EMDR second-step intervention for non-responders to CBT for Panic Disorder with or without Agoraphobia: an uncontrolled pilot study.

A feasibility study of the clinical effectiveness of Eye Movement Desensitization and Reprocessing as a second-step intervention for non-responders to Cognitive Behavioral Therapy for Panic Disorder with or without Agoraphobia”: an uncontrolled pilot study.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON26887
Enrollment
15
Registered
2019-03-11
Start date
2019-04-08
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Panic disorder

Interventions

Step 1: CBT Step 2: EMDR

Sponsors

HSK, University of Utrecht
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. a PD (with or without agoraphobia) as main classification according to DSM-5 based on the SCID-5-S (APA, 2017) 2. age above 18 years 3. sufficient mastery of Dutch to complete the questionnaires 4. less than 33.33 % symptom reduction after nine treatment sessions of CBT 5. stable medication use (type and dosage) for at least four weeks and willingness of both patient and treating physician/psychiatrist to keep it stable during the study period 6. use of anxiolytic medication is allowed, even reduction in intake this medication to engage better in treatment attending any other psychological treatment during the study is not allowed.

Exclusion criteria

Exclusion criteria: 1. very severe depression (QIDS-C = 20) 2. acute suicidality 3. current Post Traumatic Stress Disorder (DSM-5) 4. severe alcohol or substance dependence (DSM-5) 5. lifetime psychotic disorder (DSM-5).

Design outcomes

Primary

MeasureTime frame
The primary outcome measure will be severity of PD at follow up, measured with the Agoraphobic Cognitions Questionnaire (ACQ, Dutch version) and the Body Sensations Questionnaire (BSQ, Dutch version).

Secondary

MeasureTime frame
The secondary outcome measure will be severity of symptomatology and stressors of psychopathology, measured with the Symptom Questionnaire-48 (SQ-48) and related aspects as impact of future events (IFES).

Contacts

Public ContactMaarten Merkx

HSK

m.merkx@hsk.nl0031682081080

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)